Table 2.
List of lncRNAs associated with taxane-resistance in ovarian cancer.
| lncRNA | Category | Expression in OC tissue* | Expression in paclitaxel-resistant cell lines** | Mechanisms of resistance*** | Reference |
|---|---|---|---|---|---|
| UCA1 | Intergenic | N/A | ↑ | ↓ miR-129 → ↑ abcb1 | (155, 156) |
| FER1L4 | Pseudogene | ↓ | ↓ | MAPK | (177) |
| LINC01118 | Intergenic | ↑ | ↑ | ↓ miR-134 → ↑ abcc1 | (178) |
| NEAT1 | Intergenic | ↑ (paclitaxel resistance) | ↑ | ↓ miR-194 → ↑ ZEB1 | (179) |
| Xist | Intergenic | ↓ (recurrent disease) | ↓ | N/A | (180) |
| KB-1471A8.2 | Antisense | ↓ | ↓ | ↓ CDK4 | (181) |
| OIP5-AS1 | Antisense | N/A | ↓ | N/A | (182) |
The order of the lncRNAs corresponds to the appearance of the individual descriptions in the manuscript. Only the first 4 lncRNAs are described in detail in the manuscript and are selected based on substantiating evidence in the literature.
The expression of the lncRNAs in OC tissue is indicated by arrows, ↑ for higher and ↓ for lower expression in resistant patients (patient characteristics are indicated in parenthesis), compared to expression in sensitive patients. If no patient characteristics are indicated, the expression was determined in ovarian cancer tissue from patients with unspecified sensitivity to platinum drugs and normalized to adjacent or normal ovarian tissue.
The expression in paclitaxel-resistant OC cell lines is indicated by arrows; ↑ for higher and ↓ for lower expression and the drug they are resistant to is indicated in parenthesis.
The effect of lncRNAs on associated pathways, miRNAs, genes or transcription factors involved in resistance mechanisms are indicated by arrows: ↑ induction and ↓ repression.
N/A, information not available.